AMAG Pharmaceuticals, Inc. [NASDAQ: AMAG] shares went higher by 8.91% from its previous closing of $12.06, now trading at the price of $13.14, also adding 1.08 points. Is AMAG stock a buy or should you stay away?
The stock had a rather active trading session with the latest closing, by far recording 1.07 million contracts. Compared to the average trading volume of AMAG shares, the company saw a far better performance. Moreover, the stock has a 33.26M float and a +11.29% run over in the last seven days. AMAG share price has been hovering between $23.77 and $6.81 lately, and is definitely worthy of attention.
AMAG Pharmaceuticals, Inc. [NASDAQ:AMAG]: Analyst Rating and Earnings
Its stock price has been found in the range of 6.81 to 23.77. This is compared to its latest closing price of $12.06.
Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Thu 7 Nov (In 48 Days).
Fundamental Analysis of AMAG Pharmaceuticals, Inc. [AMAG]
Now let’s turn to look at profitability: with a current Operating Margin for AMAG Pharmaceuticals, Inc. [AMAG] sitting at -13.53 and its Gross Margin at +54.11, this company’s Net Margin is now -64.30%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -5.02, and its Return on Invested Capital has reached -11.90%. Its Return on Equity is -22.04, and its Return on Assets is -11.18. These metrics suggest that this AMAG Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, AMAG Pharmaceuticals, Inc. [AMAG] has generated a Total Debt to Total Equity ratio of 37.93. Similarly, its Total Debt to Total Capital is 27.50, while its Total Debt to Total Assets stands at 24.09. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -1.23, and its Long-Term Debt to Total Capital is 35.08.
What about valuation? This company’s Enterprise Value to EBITDA is 3.01 and its Total Debt to EBITDA Value is 2.95. The Enterprise Value to Sales for this firm is now 0.79, and its Total Debt to Enterprise Value stands at 0.69. AMAG Pharmaceuticals, Inc. [AMAG] has a Price to Book Ratio of 0.70, a Price to Cash Flow Ratio of 8.59.
Shifting the focus to workforce efficiency, AMAG Pharmaceuticals, Inc. [AMAG] earns $1,014,994 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.02 and its Total Asset Turnover is 0.31. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 3.01 and its Current Ratio is 3.17. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
AMAG Pharmaceuticals, Inc. [AMAG] has 35.34M shares outstanding, amounting to a total market cap of $426.20M. Its stock price has been found in the range of 6.81 to 23.77. At its current price, it has moved down by -44.74% from its 52-week high, and it has moved up 92.88% from its 52-week low.
This stock’s Beta value is currently 0.41, which indicates that it is 5.72% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 67.40. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is AMAG Pharmaceuticals, Inc. [AMAG] a Reliable Buy?
Shares of AMAG Pharmaceuticals, Inc. [AMAG], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.